BTK inhibitorFDA-approvedFirst-line
Ibrutinib
How it works
Blocks the BTK enzyme, which is involved in the signaling pathway that promotes cancer cell growth and survival.
Cancer types
Leukemia— All patients
Breast Cancer— All patients
Efficacy
In clinical trials, around 90% of patients achieved a complete remission, with a median progression-free survival of approximately 2 years.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Exercise and CLL: A Study on Quality of Life | Leukemia | preclinical | — | Source → |
| Long-term Study of Ibrutinib for Various Blood Cancers | Leukemia | phase-3 | — | Source → |
| Comparing Treatments for Newly Diagnosed Chronic Lymphocytic Leukemia | Leukemia | phase-3 | — | Source → |
| Testing Pevonedistat and Ibrutinib in Relapsed or Refractory CLL and Non-Hodgkin Lymphoma | Leukemia | phase-1 | — | Source → |
| Comparing Pirtobrutinib and Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | Leukemia | phase-3 | — | Source → |
| Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma | Melanoma | phase-2 | — | Source → |
| Nemtabrutinib vs Ibrutinib or Acalabrutinib for First-Line CLL/SLL Treatment | Leukemia | phase-3 | — | Source → |
| Rapcabtagene Autoleucel and Ibrutinib for Blood Cancers | Leukemia | phase-1 | — | Source → |
| Ibrutinib Shows Promise in Treating Rare Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Treating Older Adults with Untreated Chronic Lymphocytic Leukemia | Leukemia | phase-3 | — | Source → |
| Customizing Ibrutinib Treatment for Untreated Chronic Lymphocytic Leukemia | Leukemia | phase-2 | — | Source → |
| Testing Combination Therapy for Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Leukemia | phase-1 | — | Source → |
| Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia | Leukemia | phase-2 | — | Source → |
| Ibrutinib Therapy Linked to Atrial Fibrillation in CLL Patients | Leukemia | observational | — | Source → |
| Combining Ianalumab with Ibrutinib Improves CLL Outcomes | Leukemia | preclinical | 38.5% of patients achieved a complete response or complete response with incomplete marrow recovery at cycle 9. | Source → |
| Pirtobrutinib Shows Promise in Treating Chronic Lymphocytic Leukemia | Leukemia | phase-3 | The overall response rate was 87.0% with pirtobrutinib versus 78.5% with ibrutinib. | Source → |
| Combination Therapy Fails to Improve CLL Response, but Activates CD8 T Cells | Leukemia | phase-2 | There was 1 complete response and 9 partial responses in 10 patients evaluable for response. | Source → |
| Optimizing Ibrutinib Doses for Chronic Lymphocytic Leukemia | Leukemia | phase-1/2 | Dose reductions based on response depth or toxicity preserved comparable response rates and progression-free survival to standard dosing. | Source → |
| Researchers Test New Skin Cancer Treatment Using Tiny Lipid Carriers | Melanoma | lab-study | — | Source → |
| Ibrutinib Treatment Outcomes in High-Risk CLL/SLL Patients | Leukemia | observational | — | Source → |
| CLL Treatments May Increase Heart Risks | Leukemia | review | — | Source → |
| New Study Compares Heart Risks of CLL Treatments | Leukemia | observational | The incidence of AF/flutter was lower for acalabrutinib compared to ibrutinib [5.8% vs. 11.7%]; the incidence of HTN was also lower in the acalabrutinib cohort [15% vs. 26.3%]. | Source → |
| Zanubrutinib vs Ibrutinib for Chronic Lymphocytic Leukemia: Cost Comparison | Leukemia | phase-3 | Treating 8 patients with zanubrutinib instead of ibrutinib prevented 1 progression or death. | Source → |
| Ibrutinib Treatment Affects CLL Cells and Immune System | Leukemia | lab-study | — | Source → |
| Ibrutinib and Acalabrutinib Show Different Effects on CLL Cells | Leukemia | lab-study | — | Source → |
| Ibrutinib May Worsen Inflammation in CLL Patients | Leukemia | lab-study | — | Source → |
| Rare CLL Relapse Manifests as Spinal Cord Infiltration | Leukemia | observational | — | Source → |
| Ibrutinib Resistance in CLL Patients May Not Affect Immune Response | Leukemia | lab-study | — | Source → |
| New Study Compares Safety of Two Cancer Drugs | Leukemia | observational | Atrial fibrillation or flutter occurred in 7.1% of patients with acalabrutinib and 14.7% of patients with ibrutinib. | Source → |
| CLL Patients Retreated after Ibrutinib Plus Venetoclax May Avoid Resistance Mutations | Leukemia | phase-2 | — | Source → |
| Many elderly leukemia patients stop taking ibrutinib treatment | Leukemia | observational | — | Source → |
| Comparing Zanubrutinib and Ibrutinib for Leukemia Treatment | Leukemia | meta-analysis | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.